🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I’m happy to share that I have successfully defended my PhD dissertation and officially graduated from FSU Chemistry & Biochemistry. Special thanks to my PI Joel Smith.

Degrade proteins, not your work schedule! A new method appearing today ChemRxiv (chemrxiv.org/engage/chemrxi…) simplifies access to molecular glues (like PROTACS) to save medicinal chemists valuable time. One-step access from cheap commercial materials, a trivial experimental setup,

Sometimes, labeling things can be good. Check out Zach's latest work in J. Am. Chem. Soc. below: pubs.acs.org/doi/10.1021/ja…

Navigating Excess Complexity: Total Synthesis of Daphenylline | Journal of the American Chemical Society Sarpong Group UC Berkeley College of Chemistry Total Synthesis and Methodology Highlights Total Synthesis #Excess #Complexity #Daphenylline pubs.acs.org/doi/10.1021/ja…

15NRORC: An Azine Labeling Protocol | Journal of the American Chemical Society FSU Chemistry & Biochemistry Florida State University Magnetic Resonance News Total Synthesis and Methodology Highlights #Azine #Labelling #Protocol pubs.acs.org/doi/10.1021/ja…

Ten-Gram-Scale #TotalSynthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials by Yosuke Kaburagi, Kazunobu Kira, Kenzo Yahata, Kentaro Iso, Yuki Sato, Fumiyoshi Matsuura, Isao Ohashi, Yasunobu Matsumoto, Minetaka Isomura, Takeo Sasaki, Takashi Fukuyama, Yusuke

We’re delighted to announce the publication in Science of our studies demonstrating the activity of Nurix’s clinical-stage targeted degrader, NX-2127, against a range of acquired resistance mutations to commonly used BTK inhibitors. Read more here: bit.ly/42serld

Our paper describing the discovery and preclinical characterization of Nurix’s clinical-stage targeted degrader, NX-2127, was recently published in the Journal of Medicinal Chemistry. You can access the publication here: bit.ly/3SgsNRe

If you missed my PI's talk today, that's ok because you have a chance tomorrow to see her present some unpublished work that we are hoping discovery/med chemists will love! check if out tomorrow morning #ACSSpring2024

#Chemistry overview

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Covalent Warheads Reloaded: Emerging and Re-emerging Covalent Warheads Application in MedChem/Chemical Biology. Check it out in the new JMC paper from the Gehringer group #MedChem #DrugDiscovery #CovalentInhibitors #ChemicalProbes #ChemicalBiology pubs.acs.org/doi/10.1021/ac…

We are excited to present the speakers of ACS Organic Division 14th Graduate Research Symposium! Join us UVA on July 25-28, 2024. #2024ACSGRS #futuretalent #ACSGRS P. Andy Evans Christina Cooley Brett Fors Aleks Holownia organicdivision.org/graduate-resea…

Check out this paper from the Smith Lab!

Wonderful news! Parafilm M rules! Very well-deserved recognition after helping so many other #NobelPrize winners achieve their breakthroughs! Congratulations Moved on to @parafilmm.bsky.social

An enantioselective palladium-catalyzed allylic substitution strategy for the total synthesis of (−) aspidospermidine now published in #OrgLett by Charlotte O'Donnell in the Stark Group @Chemie_UHH go.acs.org/bxp

Thrilled to announce that $NRIX & $PFE have won the 2024 SCRIP Quris-AI Best Partnership Alliance Award recognizing our collaboration to combine ADC & TPD technologies to develop novel degrader antibody conjugates (DACs) to target cancer. #ScripAwards #Collaboration

Nurix’s SVP & Head of Medicinal, Analytical, & Computational Chemistry, Fredrick Cohen, Ph.D., will discuss the discovery & development of novel BTK degraders at the Winter Conference on Medicinal & Bioorganic Chemistry on Sun, Feb 2, 2025, at 5:55 pm MST. bit.ly/4azd9sS

$NRIX Senior Scientist Amber Guillen will present at the American Chemical Society Spring 2025 Meeting on Tuesday, March 25, 2025, at 2:00 p.m. PT. Learn more about the meeting: bit.ly/4h2BlW5 #ACSSpring2025

NRIX’s Dir. of Medicinal Chemistry, Barbara Czako, Ph.D., will discuss the discovery and development of bexobrutideg (NX-5948) at the ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 symposium taking place May 12-15, 2025, in Chicago, IL. Learn more here: bit.ly/4iAJGRF